OmniAb, Inc. (OABI)
NASDAQ: OABI · Real-Time Price · USD
1.720
-0.080 (-4.44%)
Feb 27, 2026, 4:00 PM EST - Market closed
OmniAb Employees
OmniAb had 114 employees as of December 31, 2024. The number of employees increased by 8 or 7.55% compared to the previous year.
Employees
114
Change (1Y)
8
Growth (1Y)
7.55%
Revenue / Employee
$185,035
Profits / Employee
-$558,491
Market Cap
247.60M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 114 | 8 | 7.55% |
| Dec 31, 2023 | 106 | 11 | 11.58% |
| Dec 31, 2022 | 95 | 21 | 28.38% |
| Dec 31, 2021 | 74 | 4 | 5.71% |
| Dec 31, 2020 | 70 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cibus | 159 |
| Coherus Oncology | 158 |
| Silence Therapeutics | 116 |
| C4 Therapeutics | 110 |
| Orchestra BioMed Holdings | 70 |
| Shattuck Labs | 44 |
| Surrozen | 41 |
| Sol-Gel Technologies | 34 |
OABI News
- 4 days ago - OmniAb to Participate at the Leerink Partners Global Healthcare Conference - Business Wire
- 9 days ago - OmniAb to Report Fourth Quarter 2025 Financial Results on March 4 - Business Wire
- 2 months ago - OmniAb, Inc. (OABI) Discusses Launch and Scientific Overview of OmniUltra Technology Platform Transcript - Seeking Alpha
- 2 months ago - Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies - Business Wire
- 3 months ago - OmniAb to Hold OmniUltra Virtual Investor Event on December 15 - Business Wire
- 3 months ago - OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors - Business Wire
- 4 months ago - OmniAb, Inc. (OABI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights - Business Wire